QUOTIENT
LIVE

Serial Number

98278615

Owner

Quotient Therapeutics, Inc.

Attorney

Christina M. Licursi

Filing Date

Nov 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

QUOTIENT Trademark

Serial Number: 98278615

QUOTIENT is a trademark filed by Quotient Therapeutics, Inc. on November 20, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Quotient Therapeutics, Inc. (3 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

November 20, 2023

Registration Date

Not Registered

Published for Opposition

June 23, 2026

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 17, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 26, 2026 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 16, 2026 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jul 27, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 21, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 21, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 21, 2024 GNSL
SUSPENSION LETTER WRITTEN
Mar 21, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 26, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 26, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 26, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2024 NWOS
NEW APPLICATION ENTERED
Nov 23, 2023 NWAP